151 related articles for article (PubMed ID: 34677264)
1.
Ichikawa T; Shibata M; Inaishi T; Soeda I; Kanda M; Hayashi M; Takano Y; Takeuchi D; Tsunoda N; Kodera Y; Kikumori T
Curr Oncol; 2021 Oct; 28(5):4080-4092. PubMed ID: 34677264
[TBL] [Abstract][Full Text] [Related]
2. Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways.
Zhang YD; Zhong R; Liu JQ; Sun ZX; Wang T; Liu JT
Clin Transl Oncol; 2023 Jun; 25(6):1629-1640. PubMed ID: 36630025
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
4. Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition.
Jahn JE; Best DH; Coleman WB
Exp Mol Pathol; 2010 Dec; 89(3):209-16. PubMed ID: 20840848
[TBL] [Abstract][Full Text] [Related]
5. The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.
Talia M; De Francesco EM; Rigiracciolo DC; Muoio MG; Muglia L; Belfiore A; Maggiolini M; Sims AH; Lappano R
Cells; 2020 Mar; 9(3):. PubMed ID: 32143514
[TBL] [Abstract][Full Text] [Related]
6. The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer.
Nakanishi K; Kanda M; Umeda S; Tanaka C; Kobayashi D; Hayashi M; Yamada S; Kodera Y
Gastric Cancer; 2019 Nov; 22(6):1143-1152. PubMed ID: 31055693
[TBL] [Abstract][Full Text] [Related]
7. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
Rene Gonzalez R; Watters A; Xu Y; Singh UP; Mann DR; Rueda BR; Penichet ML
Breast Cancer Res; 2009; 11(3):R36. PubMed ID: 19531256
[TBL] [Abstract][Full Text] [Related]
8. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation.
Sun Y; Wang Y; Fan C; Gao P; Wang X; Wei G; Wei J
Mol Cancer; 2014 Jun; 13():137. PubMed ID: 24889938
[TBL] [Abstract][Full Text] [Related]
9. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Manzano RG; Martinez-Navarro EM; Forteza J; Brugarolas A
Int J Oncol; 2014 Dec; 45(6):2250-66. PubMed ID: 25201346
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
11. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
12. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
13. Synaptotagmin-13 Is a Neuroendocrine Marker in Brain, Intestine and Pancreas.
Tarquis-Medina M; Scheibner K; González-García I; Bastidas-Ponce A; Sterr M; Jaki J; Schirge S; García-Cáceres C; Lickert H; Bakhti M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830411
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
15. Identification SYT13 as a novel biomarker in lung adenocarcinoma.
Zhang L; Fan B; Zheng Y; Lou Y; Cui Y; Wang K; Zhang T; Tan X
J Cell Biochem; 2020 Feb; 121(2):963-973. PubMed ID: 31625195
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
18. Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells.
Li Q; Zhang S; Hu M; Xu M; Jiang X
Int J Mol Med; 2020 Jan; 45(1):234-244. PubMed ID: 31939613
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
20. B-Cell-Mediated Immunity Predicts Survival of Patients With Estrogen Receptor-Positive Breast Cancer.
Lee S; Kang BH; Lee HB; Jang BS; Han W; Kim IA
JCO Precis Oncol; 2024 Mar; 8():e2300263. PubMed ID: 38452311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
